Novartis has positive data for a two-drug asthma regimen that forms the backbone of its efforts to take on rival GlaxoSmithKline in the respiratory market.
European regulators have accepted Novartis’ filing for a triple combination therapy for asthma known as QVM149, triggering payments to development partners Vectura and Sosei.
Sanofi and partner Regeneron have picked up an approval in Europe for Dupixent in asthma, unlocking an important new indication for the fast-growing biologic.
